PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons

Related Articles
Families in Gene Neighborhoods
June 2015
Signaling: A Platform for Opposing Functions
May 2015
Nuclear Pore Complex: A Flexible Transporter
February 2015
Nuclear Pore Complex: Higher Resolution of Macromolecules
February 2015
Nuclear Pore Complex: Integrative Approach to Probe Nup133
February 2015
Piecing Together the Nuclear Pore Complex
February 2015
iTRAQing the Ubiquitinome
July 2014
CAAX Endoproteases
August 2013
The Immune System: A Strong Competitor
June 2013
The Immune System: Strand Swapping for T-Cell Inhibition
June 2013
PDZ Domains
April 2013
Protein Interaction Networks: Adding Structure to Protein Networks
April 2013
Protein Interaction Networks: Morph to Assemble
April 2013
Protein Interaction Networks: Reading Between the Lines
April 2013
Protein Interaction Networks: When the Sum Is Greater than the Parts
April 2013
Alpha-Catenin Connections
March 2013
Cytochrome Oxidase
November 2012
Bacterial Phosphotransferase System
October 2012
Solute Channels
September 2012
Budding ensemble
August 2012
The machines behind the spindle assembly checkpoint
June 2012
G Protein-Coupled Receptors
May 2012
Revealing the Nuclear Pore Complex
March 2012
Topping off the proteasome
March 2012
Anchoring's the way
February 2012
Reading out regioselectivity
December 2011
An effective and cooperative dimer
November 2011
PDZ domains: sometimes it takes two
November 2011
Raising a glass to GLIC
August 2011
A2A Adenosine Receptor
May 2011
A growing family
February 2011
FERM-ly bound
February 2011
January 2011
Guard cells pick up the SLAC
December 2010
Zinc Transporter ZntB
July 2010
Zinc Transporter ZntB
July 2010
Importance of extension for integrin
June 2010
Spot protein-protein interactions… fast
March 2010
Alg13 Subunit of N-Acetylglucosamine Transferase
February 2010
Urea transporter
February 2010
Two-component signaling
December 2009
ABA receptor...this time for real?
November 2009
Network coverage
November 2009
Get3 into the groove
October 2009
Guanine Nucleotide Exchange Factor Vav1 and Rho GTPase Rac1
October 2009
GPCR subunits: Separate but not equal
September 2009
Proofreading RNA
July 2009
Ribonuclease and Ribonuclease Inhibitor
April 2009
The elusive helicase
April 2009
Click for cancer-protein interactions
December 2008

Research Themes Protein-protein interactions

Ribonuclease and Ribonuclease Inhibitor

PSI-SGKB [doi:10.3942/psi_sgkb/fm_2009_4]
Featured System - April 2009
Short description: The complex between ribonuclease and ribonuclease inhibitor is one of the tightest known intermolecular interactions, but researchers at the CESG are trying to change that.

The complex between ribonuclease and ribonuclease inhibitor is one of the tightest known intermolecular interactions, but researchers at the CESG are trying to change that. Ribonuclease is a small but destructive enzyme that is secreted by the pancreas and used to chew up RNA in our diet. Occasionally, however, it finds its way inside cells where it can wreak havoc on our cellular RNA molecules. To protect against this, our cells build a specific inhibitor protein that fights rogue ribonuclease molecules one-on-one.

A Tight Embrace

The structure solved by researchers at CESG (PDB entry 1z7x) shows how the human form of ribonuclease inhibitor works. As with the similar inhibitors from other organisms, human ribonuclease inhibitor (shown in blue) is a horseshoe-shaped protein that surrounds ribonuclease (shown in red) and blocks its active site. The strong binding is due in part to the large area of contact between the two proteins, and is augmented by strong electrostatic interactions. In mutagenesis studies, two amino acids in particular have been implicated: arginine 39 and arginine 91. In the complex, these form tight salt bridges with two glutamate amino acids in the inhibitor. These charged amino acids may also act as "electrostatic steering residues" that guide ribonuclease to its proper binding site on the inhibitor.

Evading Protections

The tight binding of ribonuclease with its inhibitor is a great advantage to the cell, since it effectively detoxifies the ribonuclease. In some cases, however, this is not the result that we want. Ribonuclease is toxic to cancer cells and is being tested as a possible therapy. Cancer cells, however, contain the inhibitor and quickly inactivate ribonuclease before it has a chance to kill the cell. Researchers have tried two approaches to solve this problem. First, they have tried using ribonucleases from other organisms, which are structurally different than our own ribonuclease and not strongly blocked by the inhibitor. However, they can also cause side effects because they are foreign to the human body.

Engineering Ribonuclease

An alternate approach is to change the human ribonuclease enough to block its interaction with the inhibitor. Based on the CESG crystal structure, researchers mutated the two "steering" arginine amino acids in ribonuclease, changing them to oppositely-charged aspartates. This resulted in an enzyme that is still active in the RNA-cleavage reaction, but which binds weakly to the inhibitor. To take a closer look at the CESG structure and this key electrostatic interaction, click on the image below.

The JSmol tab below displays an interactive JSmol.

Hda (PDB entry 3bos)

The Hda protein is a member of the AAA+ family of proteins. AAA+ proteins use ATP to control diverse functions in assembly and force generation. These proteins typically contain two different functional groups: a form-fitting active site that binds to ATP, and an 'arginine finger' that is involved in the ATP cleavage event. Typically, these proteins associate to bring the arginine finger of one subunit close to the nucleotide-binding site of another subunit. In this way, subtle motions o


  1. K. A. Dickson, M. C. Haigis and R. T. Raines (2005) Ribonuclease inhibitor: structure and function. Progress in Nucleic Acids Research and Molecular Biology 80, 349-374.

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health